[Central nervous system as a target for the new antihypertensive agents].
Nurminen
M L
ML
Helsingin yliopiston biolääketieteen laitos, farmakologian ja toksikologian osasto PL 8, 00014 Helsingin yliopisto. marja-leena.nurminen@helsinki.fi
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001339:Autonomic Fibers, Preganglionic / Q000187:drug effects / Q000503:physiopathology; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D054755:Imidazoline Receptors; D008526:Medulla Oblongata / Q000187:drug effects / Q000503:physiopathology; D010080:Oxazoles / Q000494:pharmacology / Q000627:therapeutic use; D011955:Receptors, Drug / Q000819:agonists / Q000378:metabolism; D000077769:Rilmenidine; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology; D013565:Sympatholytics / Q000494:pharmacology / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D007093:Imidazoles; D054755:Imidazoline Receptors; D010080:Oxazoles; D011955:Receptors, Drug; D013565:Sympatholytics; C043482:moxonidine; D000077769:Rilmenidine